Abstract
Efavirenz concentrations were measured in 21 patients during an interruption cycle of the ANRS 106 Window trial. The median efavirenz concentrations in the patients 12 h, 3 days, and 7 days after discontinuation of the drug were 1,962 ng/ml, 416 ng/ml, and 112 ng/ml, respectively. The half-life ranged from 27 to 136 h. No relationship between efavirenz exposure and detection of nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations was demonstrated. Patients who were treated by a lamivudine- or emtricitabine-based regimen had a lower risk of NNRTI mutation selection.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alkynes
-
Amino Acid Substitution
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / pharmacokinetics
-
Benzoxazines / blood
-
Benzoxazines / pharmacokinetics*
-
Chromatography, High Pressure Liquid
-
Cyclopropanes
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Drug Combinations
-
Drug Resistance, Viral
-
Emtricitabine
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Reverse Transcriptase / antagonists & inhibitors*
-
HIV Reverse Transcriptase / metabolism
-
HIV-1 / drug effects
-
HIV-1 / genetics*
-
Half-Life
-
Humans
-
Lamivudine / administration & dosage*
-
Lamivudine / therapeutic use
-
Male
-
Mutation
-
Reverse Transcriptase Inhibitors / blood
-
Reverse Transcriptase Inhibitors / pharmacokinetics*
-
Viral Load / drug effects
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Drug Combinations
-
Reverse Transcriptase Inhibitors
-
Deoxycytidine
-
Lamivudine
-
HIV Reverse Transcriptase
-
Emtricitabine
-
efavirenz